Strategies for Identity Testing of Therapeutic Oligonucleotide Drug Substances and Drug Products.
NUCLEIC ACID THERAPEUTICS(2020)
摘要
A risk-based approach for routine identity testing of therapeutic oligonucleotide drug substances and drug products is described. Risk analysis of solid-phase oligonucleotide synthesis indicates that intact mass measurement is a powerful technique for confirming synthesis of the intended oligonucleotide. Further risk assessment suggests that the addition of a second, sequence-sensitive identity test, which relies on a comparison of some property of the sample to a reference standard of proven identity, results in a sufficient test of identity for most oligonucleotide drug substances and products. Alternative strategies for drug product identity testing are presented. The analysis creates a common way to communicate risk and should result in a harmonized approach to identity testing that avoids the unnecessary analytical burden associated with routinede novosequencing, without compromising quality or patient safety.
更多查看译文
关键词
oligonucleotides,identification,sequence confirmation,risk assessment,GMP controls,intact mass measurement
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要